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Background: There are few data on tuberculosis (TB) incidence in HIV-infected children on antiretroviral therapy
(ART). Observational studies suggest co-trimoxazole prophylaxis may prevent TB, but there are no randomized data
supporting this. The ARROW trial, which enrolled HIV-infected children initiating ART in Uganda and Zimbabwe and
included randomized cessation of co-trimoxazole prophylaxis, provided an opportunity to estimate the incidence of
TB over time, to explore potential risk factors for TB, and to evaluate the effect of stopping co-trimoxazole prophylaxis.
Methods: Of 1,206 children enrolled in ARROW, there were 969 children with no previous TB history. After 96 weeks
on ART, children older than 3 years were randomized to stop or continue co-trimoxazole prophylaxis; 622 were eligible
and included in the co-trimoxazole analysis. Endpoints, including TB, were adjudicated blind to randomization by an
independent endpoint review committee (ERC). Crude incidence rates of TB were estimated and potential risk factors,
including age, sex, center, CD4, weight, height, and initial ART strategy, were explored in multivariable Cox proportional
hazards models.
Results: After a median of 4 years follow-up (3,632 child-years), 69 children had an ERC-confirmed TB diagnosis.
The overall TB incidence was 1.9/100 child-years (95 % CI, 1.5–2.4), and was highest in the first 12 weeks following
ART initiation (8.8/100 child-years (5.2–13.4) versus 1.2/100 child-years (0.8–1.6) after 52 weeks). A higher TB risk was
independently associated with younger age (<3 years), female sex, lower pre-ART weight-for-age Z-score, and current
CD4 percent; fewer TB diagnoses were observed in children on maintenance triple nucleoside reverse transcriptase
inhibitor (NRTI) ART compared to standard non-NRTI + 2NRTI.
Over the median 2 years of follow-up, there were 20 ERC-adjudicated TB cases among 622 children in the co-trimoxazole
analysis: 5 in the continue arm and 15 in the stop arm (hazard ratio (stop: continue) = 3.0 (95 % CI, 1.1–8.3), P = 0.028).
TB risk was also independently associated with lower current CD4 percent (P <0.001).
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Conclusions: TB incidence varies over time following ART initiation, and is particularly high during the first 3 months
post-ART, reinforcing the importance of TB screening prior to starting ART and use of isoniazid preventive therapy once
active TB is excluded. HIV-infected children continuing co-trimoxazole prophylaxis after 96 weeks of ART were diagnosed
with TB less frequently, highlighting a potentially important role of co-trimoxazole in preventing TB.
Keywords: Antiretroviral therapy, HIV, Incident tuberculosis, PediatricBackground
Tuberculosis (TB) remains a leading cause of morbidity
and mortality among HIV-infected patients in low-income
countries [1]. The HIV epidemic has shifted the peak age
of TB in adults to younger ages, resulting in higher TB
exposure and TB burden in children [2].
Antiretroviral therapy (ART) has been shown to reduce
TB incidence in adults and children [3–8]. Two recent
randomized controlled trials in adults showed that early
compared to deferred ART initiation reduced TB in
individuals with high CD4 counts [9, 10]. However, there
remains an elevated risk of TB compared to HIV-uninfected
individuals [11]. Despite improved access to ART, TB
remains a serious co-infection in HIV-infected children,
accounting for nearly 30 % of deaths in this population, with
the highest burden in sub-Saharan Africa [1, 12].
Recently, the role of co-trimoxazole in TB prevention
has been investigated. Observational evidence suggests
that extended use of this inexpensive and widely available
prophylactic antibiotic may reduce the risk of developing
TB in adults [13]. This is supported by in vitro data
suggesting that co-trimoxazole has anti-mycobacterial
activity [14] and synergistic activity with rifampicin [15].
However, there are no randomized data on the role of co-
trimoxazole in TB prevention.
The ARROW trial followed 1,206 HIV-infected children
in Uganda and Zimbabwe for up to 5 years after ART
initiation and included a randomized intervention to stop
or continue co-trimoxazole after 96 weeks on ART [4].
The trial showed that that extended use of co-trimoxazole
after 2 years of ART reduced hospitalizations for malaria
and non-malaria infections, such as pneumonia and sepsis
[16]. Long-term co-trimoxazole has subsequently been
recommended for all HIV-infected children [17].
Using data from the ARROW trial, the present study
had two aims: first, to calculate the incidence of TB from
ART initiation over a median of 4 years follow-up on
ART; and, second, to compare TB diagnoses in children
randomized to stop or continue co-trimoxazole after
96 weeks on ART.
Methods
ARROW trial
The ARROW trial design, methods, and results have
been described elsewhere [16, 18]. Briefly, ARROW wasa randomized controlled factorial trial comparing
outcomes of children randomized to either clinically- or
laboratory-driven monitoring and (simultaneously in a
factorial design) to either a standard three-drug or an
induction-maintenance first-line ART regimen. Children
were randomized to one of three arms: Arm A (lamivu-
dine/abacavir/non-nucleoside reverse transcriptase inhibi-
tor (NNRTI) throughout); Arm B (lamivudine/abacavir/
zidovudine/NNRTI until week 36, with subsequent
lamivudine/abacavir/NNRTI); or Arm C (lamivudine/
abacavir/zidovudine/NNRTI until week 36, with subse-
quent lamivudine/abacavir/zidovudine). A total of 1,206
children and adolescents, median age 6 years (range,
3 months to 17 years), eligible for ART following WHO
2006 [19] guidelines, were enrolled between March 2007
and November 2008 from three centres from Uganda and
one in Zimbabwe.
All children started once daily co-trimoxazole at enrol-
ment if they were not already taking it, as per the WHO
2006 [19] guidelines (200 mg sulfamethoxazole and 40 mg
of trimethoprim, 400 mg sulfamethoxazole and 80 mg of
trimethoprim, or 800 mg of sulfamethoxazole and
160 mg of trimethoprim for a body weight of 5–15,
15–30, or >30 kg, respectively). Isoniazid preventative
therapy was not routinely used, and TB screening
pre-enrolment was based on standard elicitation of
symptoms. After enrolment, children were followed at
weeks 4, 8, and 12, and then 12 weekly for up to
5 years. Children saw a nurse at every visit who soli-
cited specific symptoms and referred the child to the
doctor if unwell. Height and weight were measured at
every visit and converted to Z-scores using UK refer-
ence standards [20]. Children saw a doctor routinely
every 12 weeks for assessments including a full blood
count and CD4 T-cell count. Only 3 % of children
were lost to follow-up; 95 % remained on first-line
ART over a median of 4 years and 96 % were alive at
the end of the trial. The trial included an additional
(open-label) randomization 96 weeks after ART initi-
ation to either stop or continue taking co-trimoxazole
prophylaxis. Children over 3 years of age who had
been receiving ART for at least 96 weeks and were
using insecticide-treated bed-nets (in malaria-endemic
areas) were eligible for this randomization. Children
with previous P. jirovecii pneumonia were excluded.
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hospitalizations, the trial showed that prolonged use
of co-trimoxazole was beneficial [16].
All caregivers provided written informed consent to
participate in the study and for future publication of
data: children and adolescents provided consent or
assent, depending on age and knowledge of HIV status.
The trial was approved by ethics committees in Uganda
(Joint Clinical Research Centre IRB Office), Zimbabwe
(Medical Research Council of Zimbabwe), and the UK
(UCL Research Ethics Committee).
Diagnosis of TB in ARROW
Data on TB diagnosis were collected on a standardized
form, from enrolment and throughout follow-up. TB
was reported as either definitive or presumptive (as per
WHO diagnostic criteria for HIV-infected children) [21].
A diagnosis of TB was made based on suggestive clinical
features with available supportive investigations, including
the tuberculin skin test, chest X-ray or other imaging, and
sputum microscopy with or without culture. TB was cate-
gorized by site of infection as pulmonary, disseminated
extrapulmonary, and tuberculous lymph node disease.
All TB diagnoses and causes of death were adjudicated
blind to randomized arm by an independent Endpoint
Review Committee (ERC) using clinical summaries of
the event provided in real-time by clinicians managing
the children, and all routine and non-routine laboratory
data including history of TB contact, clinical presenta-
tion, microbiological and radiological investigations, and
response to TB treatment. Deaths were classified as TB-
related when TB was adjudicated as one of the causes of
death. The ERC also adjudicated whether, in their
opinion, the TB event was likely due to immune recon-
stitution inflammatory syndrome (IRIS); there are no
validated IRIS definitions in children.
In order to exclude the possibility of relapses from
previous TB infection, children with a reported past
history of TB (including prevalent TB at enrolment)
were excluded from the analyses.
Statistical methods
TB incidence analysis
Time to TB diagnosis was defined as time from ART
initiation to the date of the first TB diagnosis. The
incidence of TB per 100 child-years was calculated as
the number of confirmed TB diagnoses occurring within
each of the following time periods divided by the total
accrued child-time for that same period: (1) 0–12 weeks;
(2) 12–52 weeks; (3) >52 weeks. A smoothed estimate of
the incidence over time was also estimated from a flex-
ible parametric model [22]. A multivariable Cox propor-
tional hazards model was used to explore potential risk
factors for TB, including baseline age, sex, center, initialrandomized ART strategy (Arm A, B, C, as above),
randomized monitoring strategy (clinically- vs. laboratory-
driven monitoring), WHO clinical stage 3/4, and baseline
and time-updated weight/height-for-age Z-scores and
CD4 (count and %), including all factors with P <0.1 in a
univariable model in the final adjusted model. We did not
include viral load as this was measured retrospectively in
selected samples in a subset of children post-baseline.
Effect of stopping co-trimoxazole
For the co-trimoxazole analysis, time zero was the date
of the co-trimoxazole randomization, which occurred
more than 96 weeks after ART initiation. Time to TB
diagnosis in this analysis was defined as the time from
co-trimoxazole randomization to diagnosis of TB,
including any recurrences in children who had had a
previously confirmed TB diagnosis during follow-up, but
excluding children with prevalent or prior TB at ART ini-
tiation (since these diagnoses could not be confirmed).
Kaplan–Meier and multivariable Cox proportional
hazards models were fitted to estimate the unadjusted and
adjusted effect of stopping compared to continuing co-
trimoxazole on the risk of TB diagnosis. Covariates
considered for a multivariable adjusted model were as for
the TB incidence analysis, measured at the time of co-
trimoxazole randomization.
All analyses were performed in Stata (version 13).
Results
TB incidence analysis
Of the 1,206 children in the ARROW trial, 237 had a
history of TB and were excluded, leaving 969 in the
analysis (Fig. 1a). Over a median of 4 years follow-up
from ART initiation, 87 children (9 %) were diagnosed
with TB; 18 TB diagnoses (14 pulmonary and 4 extra-
pulmonary) were adjudicated as not TB by the ERC
based on established alternative diagnoses, leaving 69
incident TB cases (61 pulmonary, 3 extra-pulmonary,
and 5 lymph node TB) and 900 children with no TB at
the end of follow-up (Fig. 1a). A total of 55 (80 %) of the
69 TB cases adjudicated by the ERC were presumptive
diagnoses; 14 (20 %) were definitive.
Based on the 69 ERC-adjudicated TB cases, the overall
incidence of TB was 1.9 per 100 child-years (95 % CI,
1.5–2.4), which varied over time: 8.8/100 child-years for
the first 12 weeks, 2.7/100 child-years between 12 and
52 weeks, and 1.2/100 child-years thereafter (Fig. 2). The
smoothed hazard function indicates a peak in the first
few weeks following ART initiation with the risk falling
rapidly thereafter.
Table 1 shows the characteristics of children at ART
initiation. Overall, the median age was 5 years (IQR, 2–9),
488 (50 %) were male, and 712 (73 %) were recruited from
sites in Uganda and 257 (27 %) from Zimbabwe. Children
Fig. 1 Analysis populations: (a) main tuberculosis incidence analysis and (b) co-trimoxazole analysis
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marginally more likely to be aged <3 years at ART
initiation (45 % vs. 34 % without TB, P = 0.07), and to
be female (59 % vs. 49 %, P = 0.09); they were signifi-
cantly more likely to have a lower CD4 percent (median
8 % vs. 13 % for those without TB, P <0.001), lower
height- and weight-for-age Z scores (median −3.0 andFig. 2 Tuberculosis incidence over time after antiretroviral therapy initiation−2.8, respectively, vs. −2.3, and −1.8, respectively, both
P <0.001); and to already have WHO stage 3 or 4 HIV dis-
ease (75 % vs. 62 %, P = 0.03) at ART initiation. Additional
file 1 shows the same characteristics including chil-
dren (n = 237) with a history of TB, indicating broadly
similar results. Of note, a history of TB was not
found to be associated with future TB in this cohort.
Table 1 Baseline characteristics of children by subsequent tuberculosis (TB) status
TB No TB Total P value
69 (7 %) 900 (93 %) 969
Age (at baseline)
Median, IQR (years) 5 (2–11) 5 (2–9)
< 3 years 31 (9) 307 (91) 338 0.07
Sex
Male 28 (6) 460 (94) 488 0.09
Female 41 (9) 440 (91) 481
Centre
Entebbe 16 (9) 163 (91) 179 0.35
JCRC 16 (6) 248 (94) 264
Harare 14 (6) 243 (94) 257
PIDC 23 (9) 246 (91) 269
Height (median IQR)
Height-for-age Z score −3.0 (−4.0 to –1.8) −2.3 (−3.3 to –1.3) <0.001
Weight (median IQR)
Weight-for-age Z score −2.8 (−4.1 to –1.8) −1.8 (−2.8 to –0.9) <0.001
WHO stage
3 or 4 52 (8) 561 (92) 613 0.03
CD4 (median, IQR)
CD4 % 8 (5–13) 13 (7–19) 0.001
CD4 counta 136 (33–250) 253 (93–405) 0.07
Initial ART
3TC ABC EFV 6 (6) 99 (94) 105 0.03
3TC ABC NVP 24 (11) 190 (89) 214
ZDV 3TC ABC EFV 9 (4) 217 (96) 226
ZDV 3TC ABC NVP 30 (7) 394 (93) 30
Randomization
A (3TC/ABC/NNRTI throughout) 30 (9) 289 (91) 319
B (3TC/ABC/NNRTI throughout, ZDV until week 36) 24 (7) 301 (93) 325
C (3TC/ABC/ZDV throughout, NNRTI until week 36) 15 (5) 310 (95) 325 0.06
Randomization
Clinical monitoring 35 (7) 449 (93) 484
Laboratory monitoring 34 (7) 451 (93) 485 0.89
Values are n (row %) unless otherwise stated
aIn those over 5 years
3TC Lamivudine, ABC Abacavir, EFV Efavirenz, IQR Interquartile range, JCRC Joint Clinical Research Centre, NNRTI Non-nucleoside reverse transcriptase inhibitor,
NVP Nevirapine, PIDC Paediatric Infectious Diseases Clinic, ZDV Zidovudine
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that included nevirapine (compared to efavirenz) was as-
sociated with an increased risk of TB (P = 0.03). A lower
proportion of children in Arm C (initial 4-drug regimen
decreased to 3-drug NRTI-only regimen after 36 weeks)
developed TB compared to other groups (P = 0.06).
There was no difference in TB incidence between pa-
tients randomized to either clinical- or laboratory-driven
monitoring.Table 2 shows unadjusted and adjusted hazard ratios
from the multivariable Cox model, including effects of
the time-updated covariates. The following factors were
independently associated with the risk of developing TB:
younger age at ART initiation (P = 0.04), female sex
(P = 0.01), lower current weight-for-age (P = 0.001),
and lower current CD4 percent (P <0.001). Current
height-for-age and pre-ART WHO stage did not inde-
pendently predict TB risk. Baseline weight-for-age,
Table 2 Effects of pre-antiretroviral therapy (ART) and time-updated characteristics on the risk of developing tuberculosis (TB) after
ART initiation
HR (unadjusted) 95 % CI P aHR (adjusted) 95 % CI P
Age (at ART initiation)
< 3 years 1.0 1.0
≥ 3 years 0.63 (0.40–1.02) 0.06 0.54 (0.31–0.96) 0.04
Sex
Male 1.0 1.0
Female 1.51 (0.94–2.45) 0.09 1.88 (1.15–3.06) 0.01
Height-for-age Z score
(time-updated) 0.65 (0.55–0.78) <0.001 0.93 (0.73–1.20) 0.61
Weight-for-age Z score
(time-updated) 0.62 (0.54–0.71) <0.001 0.70 (0.56–0.86) 0.001
WHO stage (pre-ART)
1 or 2 1.0 1.0
3 or 4 1.82 (1.05–3.16) 0.03 1.32 (0.72–2.40) 0.37
CD4 %
(time-updated) 0.94 (0.92–0.97) <0.001 0.94 (0.91–0.97) <0.001
Initial ART
Included NVP 1.0 1.0
Did not include NVP 0.51 (0.29–0.92) 0.02 0.95 (0.47–1.90) 0.87
Randomization
A (3TC/ABC/NNRTI throughout) 1.0 1.0
B (3TC/ABC/NNRTI throughout, ZDV until week 36) 0.75 (0.44–1.29) 0.31 0.83 (0.48–1.43) 0.50
C (3TC/ABC/ZDV throughout, NNRTI until week 36) 0.48 (0.26–0.89) 0.02 0.43 (0.22–0.81) 0.01
Note: final model includes all factors with P <0.1 in univariable analyses (Table 1)
3TC Lamivudine, ABC Abacavir, aHR Adjusted hazard ratio, HR Hazard ratio, NNRTI Non-nucleoside reverse transcriptase inhibitor, NVP Nevirapine, ZDV Zidovudine
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when included with the corresponding time-updated
variables (data not shown).
Although a nevirapine-containing first-line ART regimen
was univariably associated with risk of TB, this was no lon-
ger significant when age and current weight were included
in the model, likely due to confounding, as all children
under 3 years started nevirapine. However, a reduced risk
of TB remained for those randomized to ART regimen C
(induction-maintenance strategy) compared to regimen A
(3-drug NNRTI-based regimen throughout) (P = 0.01). To
investigate this further we restricted the analysis to TB
incidence within 12 weeks of starting ART (with appropri-
ate censoring) when Arms B and C were the same (i.e.
a 4-drug ART regimen). Here we found no evidence of a
difference for Arm B versus A (P = 0.6), with some limited
evidence of a difference for Arm C versus A (P = 0.06),
suggesting that this could be a chance effect.
TB-associated immune reconstitution inflammatory
syndrome (TB-IRIS)
Twenty-two TB cases (32 %) were reported as likely
due to TB-IRIS, with a median time to diagnosis of20 weeks following ART initiation (IQR, 4–42) versus
100 (24–151) in non-IRIS cases. Of the IRIS cases, 17
(77 %) were presumptive TB, and notably 17 (77 %)
occurred in females.
Censoring non-IRIS cases in the same multivariable
Cox model to estimate the impact of factors on the
cause-specific hazard of developing TB-IRIS before TB
non-IRIS, showed broadly similar results to Table 2, al-
though power was lower with small numbers of events;
the only significant associations were with weight and
CD4 percent (data not shown). Censoring TB-IRIS cases
in the same multivariable Cox regression analysis to esti-
mate the impact of factors on the cause-specific hazard
of developing TB non-IRIS before TB-IRIS, showed
similar results in terms of identifying risk factors, ex-
cept that sex was no longer significant: males versus
females (HR = 1.28; 95 % CI, 0.72–2.29; P = 0.39).Outcomes
By the end of follow-up, of the 69 adjudicated TB cases,
3 (4 %) children had died compared to 43 (5 %) of those
without TB (P = 0.81), and 3 (4 %) had a further
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and 24 months after the first diagnosis).
Co-trimoxazole analysis
After 96 weeks on ART, 760 children were eligible for
the co-trimoxazole randomization; of these, 138 had a
previous history of TB and were excluded, leaving 622
children in the analysis (Fig. 1b); 310 (50 %) children
were randomized to continue co-trimoxazole and 312
(50 %) to stop, and baseline characteristics of children
were well balanced by randomized group (Additional
file 2: Table S2). Overall, 51 % were female and me-
dian age was 4 years. The median weight-for-age and
height-for-age scores were −1.3 and −1.9, respectively,
and CD4 percent was 32 %.
There were a total of 22 TB diagnoses over a median
of 2 years follow-up after co-trimoxazole randomization.
Two TB diagnoses were adjudicated as not TB by the
ERC leaving 20 incident TB cases and 602 children with
no TB at the end of follow-up. Of 20 adjudicated TB
cases, 5 were definitive (25 %) and 15 (75 %) were
presumptive.
Time to TB diagnosis by randomized group is shown
in Fig. 3. There were 5 adjudicated TB cases in the
continue arm and 15 in the stop arm (HR = 3.0; 95 % CI,
1.1–8.3; P = 0.028), comparing stopping to continuing
co-trimoxazole. Of the 5 cases in the continue arm, 1
was definitive and 4 were presumptive; of the 15 cases in
the stop arm, 4 were definitive and 11 were presumptive.
Adjusting for risk factors identified from the main
analysis (including age, sex, CD4 percent, weight and
current ART regimen) gave similar results (HR = 2.7;
95 % CI, 1.0–7.6; P = 0.055). Table 3 shows theFig. 3 Time to tuberculosis diagnosis by co-trimoxazole randomization (aftcharacteristics of the children at the time of co-
trimoxazole randomization by future TB diagnosis. On
multivariable adjustment, along with stopping co-
trimoxazole, only a lower current CD4 percent (P <0.001)
was independently associated with a higher risk of TB. Re-
peating the analysis including children (n = 138) who had
a history of TB gave similar results (data not shown).
Discussion
TB remains one of the major co-infections in HIV-
infected children, but there are scarce prospective data
on TB incidence in children starting ART. We therefore
undertook an analysis of incident TB using prospectively
collected data from the ARROW trial in Uganda and
Zimbabwe, which is the largest pediatric trial to date of
children initiating ART in Africa. We show here that TB
incidence is much higher in HIV-infected children than
in the general population in these countries, and that
the risk is particularly high in the first 3 months of treat-
ment. Strikingly, despite good immune reconstitution
after 2 years of ART, continuation of co-trimoxazole led
to significant reductions in incident TB, suggesting an
additional role for co-trimoxazole prophylaxis in settings
of high TB burden.
Available data on TB incidence in children on ART are
mostly limited to retrospective analyses and observational
cohorts [4–8, 23], with the inherent problems of missing
data and loss to follow-up. The ARROW trial, which
enrolled children in two countries with high HIV-TB
burden, had a large sample size, high rates of follow-up
over 4–5 years, and independently adjudicated clinical
endpoints. We estimated an overall TB incidence rate of
1,900 per 100,000 child-years. This incidence is more thaner 96 weeks on antiretroviral therapy)
Table 3 Characteristics of children who did and did not develop tuberculosis (TB) following co-trimoxazole randomization
At co-trimoxazole randomization TB No TB Total P value
20 (3 %) 602 (97 %) 622
Randomization
Stop co-trimoxazole 15 (5) 297 (95) 312
Continue co-trimoxazole 5 (2) 305 (98) 310 0.024
Age (at co-trimoxazole randomization)
Median, IQR 6.5 (3.5–11.5) 7 (4–10)
<5 years 10 (3) 280 (97) 290 0.75
Sex
Male 8 (3) 295 (97) 303
Female 12 (4) 307 (96) 319 0.43
CD4 median IQR (time-updated)
CD4 % 18 (11.5–31) 33 (26–38) <0.001
Weight median IQR (time-updated)
Weight-for-age Z score −1.0 (−2.1 to –0.5) −1.3 (1.9 to –0.6) 0.60
Height median IQR (time-updated)
Height-for-age Z score −1.8 (−3.0 to –0.9) −1.9 (−2.7 to –1.1) 0.92
WHO stage (pre-ART)
3 and 4 13 (3) 378 (97) 391 0.84
ART randomization
A (3TC/ABC/NNRTI throughout) 8 (4) 192 (96) 200
B (3TC/ABC/NNRTI post week 36) 8 (4) 210 (96) 218
C (3TC/ABC/ZDV post week 36) 4 (2) 200 (98) 204 0.46
ART at co-trimoxazole randomization
3TC ABC EFV 4 (3) 134 (97) 138
3TC ABC NVP 11 (4) 245 (96) 256
ZDV 3TC ABC 4 (2) 196 (98) 200
Other 1 (4) 27 (96) 28 0.58
Values are n (row%) unless otherwise stated
3TC Lamivudine, ABC Abacavir, ART Antiretroviral therapy, EFV Efavirenz, IQR Interquartile range, NNRTI Non-nucleoside reverse transcriptase inhibitor, NVP Nevirapine,
ZDV Zidovudine
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Kampala district [24] and more than 50 times higher than
notified rates of childhood TB in Zimbabwe [1]. In fact,
the rates of TB in HIV-uninfected children would be even
lower than in these reports as a substantial proportion of
children included in these surveys were HIV-infected [24].
The incidence of TB disease varied over time following
ART initiation and was highest in the first 3 months
(8,800/100,000 child-years), as also observed in adults
[25]. High TB rates in the first few months following
ART initiation have been reported previously in children
[4–8, 26]; contributory factors include undiagnosed
prevalent TB, unmasking of TB as result of immune
reconstitution (TB-IRIS), and ongoing risk due to pre-
ART immune suppression and the required time for
CD4 reconstitution. Compared to the first 3 months of
ART, the rates of TB decreased 7-fold after 12 months,showing the benefits of ART in TB prevention. However,
TB incidence after 1 year of ART still remained more
than 25 times higher than that reported in pediatric pop-
ulations in Uganda and Zimbabwe [1, 24]. These higher
rates of TB on established ART may be due to higher
exposure risk in HIV-infected households as well as to
increased risk of relapse due to incomplete restoration
of functional TB-specific immunity, despite numerical
recovery of CD4 cells [27]. This is an important finding
in the current era of universal ART recommendation
for HIV-infected children, and suggests an additional
benefit of early ART initiation, in line with recent
trials in adults [9, 10].
The main predictors for developing TB were lower
weight-for-age Z-score and lower CD4 percent. These are
well-reported risk factors for overall mortality in HIV-
infected children and highlight the importance of ART
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screening prior to starting ART, particularly in malnour-
ished and severely immunocompromised children. We
also found some evidence that children younger than
3 years were at a higher risk, consistent with the natural
history of TB, in which risk of progression from latent to
active disease is greater at younger ages, likely due to less
robust TB-specific immune responses [28, 29]. We found
that female sex was associated with TB diagnosis, which
seemed particularly driven by higher rates of TB-IRIS in
girls. The association with sex is difficult to explain, and
could be a chance finding given the relatively small
number of TB diagnoses overall. However, there is an
emerging literature on the influence of sex on outcome of
infectious diseases from infancy onwards [30], which may
be due to physiological or behavioral differences between
sexes [31]. The sex bias may vary with age, indicating the
influence of sex hormones on immune function at differ-
ent stages of the life cycle. In adults, TB cases among men
generally exceed those among women [32]. However, in
children, a higher frequency of extra-pulmonary TB was
reported among girls compared to boys [33].
We observed that children on a 4-drug induction-
maintenance regimen including an NNRTI for the first
36 weeks were less likely to be diagnosed with TB com-
pared to a standard 3-drug ART regimen. This may be a
chance finding as we did not observe this same reduction
in Arm B, where children were taking the same regimen
up to week 36 (when restricting the analysis to TB cases
within the first 12 weeks).
We showed that prolonged use of co-trimoxazole sig-
nificantly reduced the risk of developing TB, despite
high CD4 counts after 2 years of ART. Although there
were relatively few events, the observed effect of co-
trimoxazole on risk reduction was marked, with a 3-fold
reduction in TB incidence among those continuing,
compared to those stopping, co-trimoxazole. This is the
first randomized evidence to support the epidemiological
and in vitro observations regarding a potential prophy-
lactic effect of co-trimoxazole on mycobacteria.
TB diagnosis in HIV-infected children is reputably
challenging and TB over-diagnosis was possible; there-
fore, some reductions among children continuing co-
trimoxazole may have been due to other respiratory
infections diagnosed as TB. With no good current
diagnostic methods for TB available in children [34], it
will not be possible to increase the precision of child-
hood TB diagnosis in the near future. Therefore, it is
important not only to prevent TB but also to prevent
other respiratory infections that are frequently misdiag-
nosed as TB, to avoid prolonged anti-TB treatment.
This may be particularly important for HIV-infected
children who are frequently exposed to recurrent TB
treatment [35] and who face numerous toxicities anddrug-to-drug interactions between rifampicin and certain
antiretrovirals.
The high risk of incident TB in this analysis, despite
ART, highlights the importance of adjunctive strategies
to reduce TB acquisition. Isoniazid preventative treat-
ment at the start of ART has been recently shown to be
more effective in reducing TB in HIV-infected adults in
the TEMPRANO 12136 trial compared to ART alone
[10]. Universal IPT recommendations for HIV-infected
children were issued in 2012 [36], after the ARROW trial
finished. In ARROW, only 36 (3 %) children reported
taking isoniazid preventive treatment (IPT) and none of
those on IPT developed TB. Whilst IPT is very effective
in HIV-infected children who are exposed to TB [37],
the role of pre-exposure IPT in children receiving ART
has been debated. Madhi et al. [38] showed no benefit of
isoniazid in children aged <1 year who were not exposed
to TB. The lack of availability of single isoniazid formula-
tions in developing countries, where isoniazid is mainly
procured as co-formulated tablets with other anti-TB
medications, has been a substantial barrier for implemen-
tation of IPT in HIV-infected adults and children [39].
This study had certain limitations. Most of the TB
cases were presumptive because of the inherent chal-
lenges in confirming pediatric TB [40]. TB diagnosis is
even more difficult in HIV-infected children as TB and
HIV have overlapping clinical presentations, and chil-
dren with HIV have frequent respiratory comorbidities.
Consequently, TB in HIV-infected children in ARROW
may have been under- or over-diagnosed. One strength
of our study was that all reported TB events were
reviewed by an independent ERC, and events that were
adjudicated as unlikely due to TB were excluded or re-
classified. The open-label design of the co-trimoxazole
randomization could have led to bias in caregiver
health-seeking behavior or clinician diagnoses; however,
an effect of co-trimoxazole on TB prevention was not
anticipated and adjudication of the events was under-
taken blind to randomized group.
Conclusions
In summary, this study showed that TB rates in HIV-
infected children on ART are many-fold higher than
those in the general pediatric population, particularly
during the first 3 months of ART. These findings
emphasize the importance of TB screening prior to ART
initiation and the need to implement effective preventive
treatment in HIV-infected children without active TB
disease. Co-trimoxazole appears to reduce incident TB in
HIV-infected children, even after several years of ART,
and may contribute to preventing TB alongside the use of
IPT. A co-formulated fixed dose combination of co-
trimoxazole, isoniazid, and vitamin B6 has been recently
developed for adults and older children and is being
Crook et al. BMC Medicine  (2016) 14:50 Page 10 of 11evaluated using this formulation in the REALITY trial [39,
41]. While a formulation still needs to be developed for
younger children, this fixed dose combination could
resolve unacceptably slow implementation of universal IPT
and inadequate co-trimoxazole coverage in this population.
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